| Literature DB >> 24988417 |
Vijay K Sharma1, Saroj K Das1, Priyanka Dhar1, Kalpana B Hota1, Bidhu B Mahapatra2, Vivek Vashishtha1, Ashish Kumar1, Sunil K Hota1, Tsering Norboo3, Ravi B Srivastava1.
Abstract
Though acute exposure to hypobaric hypoxia is reported to impair cognitive performance, the effects of prolonged exposure on different cognitive domains have been less studied. The present study aimed at investigating the time dependent changes in cognitive performance on prolonged stay at high altitude and its correlation with electroencephalogram (EEG) and plasma homocysteine. The study was conducted on 761 male volunteers of 25-35 years age who had never been to high altitude and baseline data pertaining to domain specific cognitive performance, EEG and homocysteine was acquired at altitude ≤240 m mean sea level (MSL). The volunteers were inducted to an altitude of 4200-4600 m MSL and longitudinal follow-ups were conducted at durations of 03, 12 and 18 months. Neuropsychological assessment was performed for mild cognitive impairment (MCI), attention, information processing rate, visuo-spatial cognition and executive functioning. Total homocysteine (tHcy), vitamin B12 and folic acid were estimated. Mini Mental State Examination (MMSE) showed temporal increase in the percentage prevalence of MCI from 8.17% on 03 months of stay at high altitude to 18.54% on 18 months of stay. Impairment in visuo-spatial executive, attention, delayed recall and procedural memory related cognitive domains were detected following prolonged stay in high altitude. Increase in alpha wave amplitude in the T3, T4 and C3 regions was observed during the follow-ups which was inversely correlated (r = -0.68) to MMSE scores. The tHcy increased proportionately with duration of stay at high altitude and was correlated with MCI. No change in vitamin B12 and folic acid was observed. Our findings suggest that cognitive impairment is progressively associated with duration of stay at high altitude and is correlated with elevated tHcy in the plasma. Moreover, progressive MCI at high altitude occurs despite acclimatization and is independent of vitamin B12 and folic acid.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24988417 PMCID: PMC4079650 DOI: 10.1371/journal.pone.0101448
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Basic inclusion criteria (Eligibility criteria L1) for volunteers enrolled for the study.
| Parameters | Value |
| Age (Years) | 27.3±2.34 |
| Birth altitude range (Min-Max, M, MSL) | 213–305 |
| Duration of stay at high altitude (Years) | 0 |
| Education (Years) | 12±2 |
| Income per month (INR) | 18000±2243 |
|
| |
| Any serious health illness | No |
| Head injury resulting in loss of consciousness | No |
| Any form of seizers, delirium tremens or convulsions | No |
| Allergies to medication, foods, animals, chemicals or other agents | No |
| Lung diseases such as asthma, emphysema, or chronic bronchitis | No |
| Surgeries or hospitalizations | No |
| Hypertensions | No |
| Diabetes | No |
| Viral hepatitis | No |
| Dementia/Memory Impairment | No |
| Stroke/Infarction/Cerebral Hemorrhage | No |
| Kidney disease | No |
| GERD symptoms | No |
| Chest pain | No |
| Congenital heart disease | No |
| Neurological Problem/Epilepsy | No |
| Cancer | No |
| Heart attack or any heart problem | No |
| Familial disorders | No |
Eligibility Criteria L2 comprising of core behavioral measures (CBM), Beck Depression Inventory (BDI), Mini Mental State Examination (MMSE), Lake Louise Score for Acute Mountain Sickness and baseline characteristics for kidney function, lipid profile, liver function and blood glucose.
| Core Behavioral Measures (%) | Values |
|
| |
| No Consumption (%) | 97.7 |
| Mild Consumption (%) | 2.3 |
| Moderate Consumption (%) | Nil |
| Severe Consumption (%) | Nil |
|
| |
| No Smoker | 95.7 |
| Mild Smoker (%) | 4.3 |
| Moderate Smoker (%) | Nil |
|
| |
| Mild (%) | 82.43 |
| Moderate (%) | 16.52 |
| Severe (%) | 1.05 |
| Severe Smoker (%) | Nil |
| Beck Depression Inventory (BDI)(Score) | 5.23±1.34 |
| Mini Mental State Examination(Score) | 28.01 ±0.72 |
| Lake Louise Score | 0 |
|
| |
|
| |
| Blood Urea Nitrogen (6–20 mg/dl) | 9.3±1.1 |
| Creatinine (0.9–1.3 mg/dl) | 1.01±0.11 |
|
| |
| Cholesterol (<200 mg/dl) | 139.9±24.1 |
| Triglycerides (<150 mg/dl) | 82.3±26.2 |
| HDL (40–60 mg/dl) | 46.5±5.3 |
| LDL (<100 mg/dl) | 81.4±12.3 |
| Chol/HDL Ratio (<3.3) | 2.95±0.28 |
| LDL/HDL Ratio (<3.0) | 1.88±0.5 |
| VLDL (≤30 mg/dl) | 16.5±5.2 |
|
| |
| SGOT (15–37 U/L) | 27.8±5.0 |
| SGPT (30–65 U/L) | 40.16±7.57 |
|
| |
| Fasting Glucose | 83.02±3.91 |
Values depicted either as percentage or as Mean±SD of the study population.
Figure 1Flow chart showing study design and study population size at baseline and follow-ups.
Physiological Characteristics at baseline and during different durations of stay at high altitude.
| Parameters | Baseline | Follow-up 1 (After 3 months) | Follow-up 2 (After 12 months) | Follow-up 3 (After 18 months) |
| SpO2 (%) | 97.40±0.62 | 89.03 | 91.24 | 91.31 |
| PULSE RATE | 77.18±1.54 | 80.64 | 80.60 | 82.25 |
| W/H Ratio | 0.90±0.04 | 0.89±0.03 | 0.88±0.06 | 0.89±0.08 |
| BMI | 23.13±1.30 | 23.46±1.61 | 21.86±1.37 | 21.13±1.14 |
| SBP (mm Hg) | 120±1.23 | 122±1.83 | 122±1.75 | 121±1.77 |
| DBP (mm Hg) | 81±1.01 | 83±2.18 | 82±1.60 | 82±1.13 |
Values depict Mean±SEM,
*denotes P<0.05 when compared to baseline values.
Assessment of cognitive impairment using Mini Mental State Examination (MMSE), Multi Domain Cognitive Screening Test (MDCST), Raven Standard Progressive Matrices (RSPM), Clock Drawing Test (CDT), Bender Visual Motor Gestalt Test (BGT), Facial Recognition Test (FRT), Serial Digit Learning test (SDLT), Stroop Color Word Interference Test-TBAG Form (SCWT), Verbal fluency test (VFT), Visual-aural digit span test-B (VADS-B) during baseline and follow-ups.
| PARAMETERS | Baseline (n = 761) | Follow up 1 (n = 758) | Follow up 2 (n = 744) | Follow up 3 (n = 727) | |||
| CNP (n = 696) | MCI (n = 62) | CNP (n = 651) | MCI (n = 93) | CNP (n = 592) | MCI (n = 135) | ||
| MMSE | 27.20±0.27 | 27.20±0.43 | 25.20±0.62 | 28.40±0.92 | 24.20 | 28.00±0.52 | 24.40 |
| MDCST | 38.63±2.87 | 37.50±2.78 | 32.63±1.73 | 37.43±2.04 | 30.70 | 38.37±1.82 | 28.01 |
| I. Orientation | 4.50±0.49 | 3.88±0.86 | 4.13±0.00 | 4.26±0.69 | 4.10±0.88 | 4.55±0.51 | 3.19 |
| II. Visuospatial Executive | 3.98±0.97 | 3.13±1.55 | 2.13 | 3.78±0.90 | 2.20 | 3.79±0.90 | 2.00 |
| III. Attention & problem solving | 4.53±0.88 | 5.00±0.00 | 3.47 | 4.57±0.79 | 3.40 | 4.41±0.56 | 3.16 |
| IV. Memory Registration & immediate recall | 4.78±0.48 | 5.00±0.00 | 4.54±0.28 | 4.87±0.34 | 4.80±0.42 | 5.00±0.00 | 4.58±0.42 |
| V. Object recognition & remote memory | 4.83±0.38 | 4.88±0.35 | 5.00±0.00 | 4.83±0.39 | 4.80±0.42 | 4.83±0.38 | 4.95±0.23 |
| VI. Mind Body Coordination and Learning | 3.85±1.42 | 3.75±0.89 | 3.33±0.58 | 3.91±0.85 | 2.60 | 3.24±0.79 | 1.95 |
| VII. Language | 3.60±1.15 | 3.50±1.31 | 2.74±1.00 | 3.43±0.95 | 2.90±1.45 | 3.69±1.14 | 2.95±1.22 |
| VIII. Delayed Recall | 4.70±0.30 | 4.38±0.92 | 4.00±1.00 | 4.00±0.95 | 3.40 | 4.21±0.94 | 3.13 |
| IX. Procedural Memory | 4.88±0.22 | 4.86±0.24 | 4.64±0.24 | 4.78±0.28 | 3.50 | 4.59±0.32 | 2.89 |
| VISUO SPATIAL ABILITY | |||||||
| RSPM | 41.03±7.65 | 38.21±8.21 | 65.01 | 43.84±9.13 | 67 | 40.61±5.72 | 69.81 |
| BGT | 1.21±0.92 | 1.52±1.09 | 1.87±1.01 | 1.08±0.79 | 1.04±0.74 | 1.92±1.27 | 1.51±1.07 |
| CDT | 0 | 0 | 1.93 | 0 | 2.17 | 0 | 2.30 |
| ATTENTION | |||||||
| SDLT | 14.83±4.12 | 12.97±3.47 | 5.19 | 14.38±3.17 | 6.53 | 15.03±4.21 | 5.07 |
| SCWT | 32.83±11.07 | 31.40±9.25 | 69.41 | 33.71±10.86 | 73.19 | 30.51±11.09 | 71.28 |
| Trail making Test PART A | 22.13±6.03 | 20.82±3.52 | 23.21±7.47 | 24.91±8.34 | 28.49±7.31 | 21.37±6.57 | 20.67 |
| Trail making Test PART B | 43.71±8.21 | 39.91±5.97 | 41.52±6.39 | 40.82±5.70 | 38.64±7.48 | 40.36±6.31 | 39.72±6.92 |
| MEMORY AND LANGUAGE ABILITY | |||||||
| VFT-Birds | 17.56±2.81 | 18.31±5.72 | 17.28±3.18 | 17.53±4.72 | 18.94±3.85 | 18.71±5.03 | 17.27±2.93 |
| VFT-Animals | 28.51±3.62 | 27.04±4.29 | 25.93±3.75 | 28.39±4.76 | 27.21±2.21 | 25.01±7.03 | 26.54±3.73 |
Value depicts Mean±SD,
*denotes P-value <0.05 when compared to baseline data.
Figure 2Percentage prevalence of mild cognitive impairment in study population during baseline and follow-ups.
Percentage of participants with mild cognitive impairment (MCI) increased progressively with duration of stay at high altitude.
Amplitudes (µV) of EEG wave components at different electrode positions.
| ROI | Wave | Baseline | Followup 1 | Followup 2 | Followup 3 | ||||
| Normal | MCI | Normal | MCI | Normal | MCI | Normal | MCI | ||
|
|
| 41.44±1.61 | NA | 41.28±1.88 | 39.63±2.05 | 40.12±0.51 | 41.59±1.71 | 41.13±1.35 | 39.31±0.41 |
|
| 14.23±2.23 | NA | 15.14±1.33 | 11.63±1.81 | 14.11±0.75 | 10.63±1.19 | 14.31±1.07 | 13.6±1.72 | |
|
| 15.11±1.73 | NA | 16.21±1.02 | 18.53 | 14.23±1.92 | 21.91 | 15.71±1.91 | 24.79 | |
|
| 6.62±1.84 | NA | 7.78±1.12 | 6.94±0.58 | 6.18±1.92 | 4.09 | 6.41±0.4 | 5.93±1.12 | |
|
|
| 45.8±1.43 | NA | 41.15±1.31 | 40.13±0.39 | 38.12±1.91 | 40.18±0.49 | 41.06±1.05 | 39.01±1.01 |
|
| 14.68±1.00 | NA | 15.35±1.32 | 19.72±1.77 | 15.41±1.41 | 21.19±1.62 | 15.98±1.51 | 16.65±2.67 | |
|
| 14.56±1.97 | NA | 16.16±1.37 | 20.02 | 15.01±1.3 | 21.37 | 15.22±0.93 | 23.14 | |
|
| 6.45±1.89 | NA | 6.2±1.5 | 6.4±1.13 | 6±0.9 | 4.4 | 5.5±1.92 | 5.01±0.92 | |
|
|
| 39.4±1.74 | NA | 39±1.23 | 38.1±0.92 | 39.14±1.21 | 39.06±0.90 | 36.09±1.67 | 37.08±1.07 |
|
| 14.17±1.04 | NA | 14.99±1.47 | 13.89±1.92 | 15.16±1.7 | 14.09±1.01 | 14.01±0.75 | 14.89±1.57 | |
|
| 16.63±1.64 | NA | 15.14±1.08 | 21.62 | 15.21±0.68 | 22.91 | 16.23±1.09 | 21.03 | |
|
| 6.7±1.62 | NA | 6.3±1.11 | 6.00±1.92 | 6.03±1.39 | 5.9±0.93 | 6.89±1.08 | 5.08±1.33 | |
|
|
| 39.33±1.05 | NA | 38.13±2.01 | 40.61±1.41 | 39.49±1.24 | 39.73±1.01 | 41.09±1.17 | 38.53±1.25 |
|
| 13.19±1.73 | NA | 12.71±1.59 | 11.93±2.84 | 13.11±1.04 | 12.19±1.21 | 13.74±1.42 | 12.04±1.09 | |
|
| 16.34±1.96 | NA | 16.05±1.03 | 19.91±2.42 | 15.35±1.03 | 23.59 | 14.76±1.23 | 21.06 | |
|
| 6.2±1.24 | NA | 6.7±1.38 | 6.18±1.39 | 6.79±1.34 | 6.58±0.99 | 5.17±1.79 | 6.17±1.82 | |
Value depicts mean ± SEM,
*denotes P-value <0.001 when compared to baseline values. ROI: region of interest.
Figure 3Representative brain maps of alpha, beta and delta components of EEG of the same participant during baseline and follow-ups.
Scale bar shows regional activity in mkV.
Figure 4Population distribution of a) Homocysteine b) Vitamin B12 and c) Folic acid during baseline and follow-ups.
* denotes P-value <0.001 when compared to baseline data.
Correlation of homocysteine, vitamin B12 and folic acid with mild cognitive impairment.
| MMSE Score | ||
|
| ||
| Follow-ups | Correlation Coefficient (r) |
|
|
| ||
| Baseline | ||
| First | −0.431 |
|
| Second | −0.345 |
|
| Third | −0.838 |
|
|
| ||
| Baseline | ||
| First | 0.098 | 0.875 |
| Second | 0.117 | 0.852 |
| Third | 0.21 | 0.472 |
|
| ||
| Baseline | ||
| First | 0.532 | 0.356 |
| Second | 0.108 | 0.737 |
| Third | 0.105 | 0.721 |
*denotes P-value <0.05 when compared to baseline data. ‘r’ denotes Pearson product moment correlation analysis with no adjustment.